On Monday 3 October, the kick-off of our CureQ consortium was held: an introduction of all those involved who will work together over the next 5 years on predicting, delaying and curing the hereditary polyglutamine brain diseases Huntington, SCA1 and SCA3 (www.cureQ.nl).
Researchers and neurologists from various Dutch universities, various HBO courses, ethicists, biotechnology companies, patient associations and the Proefdiervrij foundation will collaborate in this study, with the aim of enabling a person-oriented approach and treatment for Huntington’s and SCAs.
From the LUMC Susanne de Bot (NEUR), Monique Mulder (CCB) and Willeke van Roon-Mom (HG) are involved in this project.
CureQ consortium kick-off meeting